Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 5Completed 4Active not recruiting 3Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 174Other hematologic neoplasm 124Breast 61Plasma cell 37Myeloid 31Gastrointestinal 30CNS 27Sarcoma 24Dermatologic 23Other solid neoplasm 18Gynecologic 18Thoracic 16Genitourinary 12Classical hematology 11Tumor-Agnostic 6Head & Neck 6NET 3Endocrine 3Other neoplasm 1

Conditions

Non-Malignant Neoplasm 1

Interventions

Magnetic Resonance Spectroscopy 3Biopsy 3fludarabine 2Taxes 2Paclitaxel 2Endoscopic Mucosal Resection 2Aminolevulinic Acid 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2venetoclax 1trametinib 1toripalimab 1thymoglobulin 1taxane 1sintilimab 1potassium oxonate 1lutetium Lu 177 dotatate 1gimeracil 1fludarabine phosphate 1dabrafenib 1apatinib 1Whole-Body Irradiation 1Watchful Waiting 1Transurethral Resection of Prostate 1Tegafur 1Surgical Procedures, Operative 1Stem Cell Transplantation 1Standard of Care 1Specimen Handling 1Sirolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Cyclophosphamide × Other neoplasm × Clear all
NCT04083183 2025-12-18

Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases

Fred Hutchinson Cancer Center

Phase 1/2 Recruiting
40 enrolled
Other neoplasm

Non-Malignant Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡